The potential to personalize treatment of severe COVID-19 patients
Over 500 patient samples were measured on the #MeMedKey platform. Preliminary results suggest that IP-10, a host-protein that plays a key role in our immune response to the virus, can be valuable in predicting disease severity and personalizing treatments that modify the immune response.
“We’re excited to join forces with our colleagues at Rabin Medical Center for this pivotal study,” said Eran Eden, MeMed’s co-founder and CEO. “The collaboration builds on years of work developing a technology that decodes the signals of the immune system and provides physicians with vital insights to make better informed treatment decisions. We’re grateful to our research collaborators and proud to be part of a team that is focused on addressing significant clinical dilemmas, working towards solutions that meaningfully improve care and outcomes for COVID-19 patients.”